|
RHBDD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.11549999967953E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.92430000000621E-05 |
| Normal-vs-Stage2 |
9.7781000000019E-05 |
| Normal-vs-Stage3 |
1.58220000434639E-08 |
| Normal-vs-Stage4 |
1.54244999999165E-05 |
| Stage1-vs-Stage2 |
3.169800E-01 |
| Stage1-vs-Stage3 |
1.457830E-02 |
| Stage1-vs-Stage4 |
1.529570E-01 |
| Stage2-vs-Stage3 |
4.473200E-01 |
| Stage2-vs-Stage4 |
8.715800E-01 |
| Stage3-vs-Stage4 |
5.338800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.12080000011805E-07 |
| Normal-vs-AfricanAmerican |
2.548100E-02 |
| Normal-vs-Asian |
8.762800E-04 |
| Caucasian-vs-AfricanAmerican |
2.895200E-01 |
| Caucasian-vs-Asian |
5.400200E-01 |
| AfricanAmerican-vs-Asian |
5.802000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.49629997281409E-09 |
| Normal-vs-Female |
2.1874999999949E-05 |
| Male-vs-Female |
5.837900E-03 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.240600E-04 |
| Normal-vs-Age(41-60Yrs) |
3.02100000015848E-07 |
| Normal-vs-Age(61-80Yrs) |
1.15670000022661E-07 |
| Normal-vs-Age(81-100Yrs) |
1.298500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.890200E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.163800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.287200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.294400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.809400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.589600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.274420E-02 |
| Classical-VS-Follicular |
6.355500E-02 |
| Classical-VS-Other |
5.594200E-02 |
| Classical-VS-Normal |
4.0496000000001E-05 |
| Tall-VS-Follicular |
4.435600E-01 |
| Tall-VS-Other |
2.735600E-01 |
| Tall-VS-Normal |
5.89110000004389E-07 |
| Follicular-VS-Other |
2.611400E-01 |
| Follicular-VS-Normal |
1.56114999999568E-05 |
| Other-VS-Normal |
7.827200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.22130000002052E-06 |
| Normal-vs-N1 |
1.45019999997498E-06 |
| N0-vs-N1 |
2.782000E-01 |
|
|
